Yellow Fever Vaccine
- Atc Codes:J07BL
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Belgium: Stamaril; Bulgaria: Stamaril; Czech Republic: Stamaril; Denmark: Stamaril; Estonia: Stamaril; Finland: Stamaril; France: Stamaril; Germany: Gelbfieber-Lebend-Impfstoff; Ireland: Stamaril; Italy: Stamaril; Luxembourg: Stamaril; Netherlands: Arilvax; Poland: Stamaril; Portugal: Stamaril; Romania: Stamaril; Slovakia: Stamaril; Slovenia: Stamaril; Spain: Stamaril; Sweden: Stamaril; UK: Stamaril.
North America
Canada: YF-VAX.
Drug combinations
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines. Live Viral Vaccine. (ATC-Code: J07BL).
Mechanism of action
A lyophilized preparation of live, attenuated organisms of 17D-204 strain of yellow fever virus. Yellow fever vaccine stimulates active immunity to yellow fever virus infection by inducing production of yellow fever virus-specific IgM-neutralizing antibodies.
Therapeutic use
Induction of active immunity against yellow fever virus.
Pregnancy and lactiation implications
Animal reproduction studies not conducted. Vaccine should be administered if travel to endemic area is unavoidable and infant should be monitored after birth. Breast-feeding contraindicated, particularly in infants <9 months of age, due to theoretical risk of encephalitis.
Unlabeled use
Contraindications
Hypersensitivity to egg or chick embryo protein, or any component of the formulation. Children <6-9 months of age. Acute or febrile disease. Immunosuppressed patients. Breast-feeding women.
Warnings and precautions
Anaphylactoid/hypersensitivity reactions might occur. Use contraindicated in immediate-type hypersensitivity reactions to eggs. Immunization should be delayed during the course of acute or febrile illness. Use with caution in severely immunocompromised patients (e.g. patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high-dose corticosteroids and patients <24 months after hematopoietic stem cell transplant)), since they may have reduced response to vaccination. Immunosuppressed patients have theoretical risk of encephalitis with yellow fever vaccine administration. Use with caution in the elderly (increased risk of adverse events in patients ≥65 years of age). Avoid use in pregnant women unless travel to high-risk areas is unavoidable. Product may contain gelatin. Packaging may contain natural latex rubber.